Administering Bispecifics in the Community vs Academic Centers

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Issam S. Hamadeh, PharmD, BCPS, BCOP

Key Takeaways

Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Patient-specific factors, including comorbidities and previous treatment responses, are crucial in determining the appropriate dosing schedule and formulary inclusion.

Panelists discuss understanding the comparative advantages, decision-making factors, infrastructure requirements, and partnership models for administering bispecific antibodies in community vs academic settings, with particular focus on patient care logistics and referral pathways.

EP: 1.Current Landscape of Bispecific Therapies for RRMM

EP: 2.Operationalizing Bispecific Therapy and the Impact of CAR-T Advancements on Sequencing

EP: 3.Best Practices for Standardizing Step-Up Dosing

EP: 4.Dosing Frequency and Formulary Decisions for Bispecific Antibodies

EP: 5.Resources and Education for Operationalizing Bispecifics

EP: 6.Safety Profiles of Bispecific Antibodies for RRMM

EP: 7.Preventing CRS and ICANS Across Sites of Care

EP: 8.Managing CRS and ICANS: Approaches and Protocols

EP: 9.Infection Prevention and Leveraging EHR for Bispecific Therapy Management

EP: 10.Navigating REMS Requirements and Educating Other Stakeholders on Bispecific Therapies

Now Viewing

EP: 11.Administering Bispecifics in the Community vs Academic Centers

Video content above is prompted by the following

What are the benefits of administering bispecific antibodies in the community setting compared with tertiary centers?
What factors might influence the decision to administer these agents at an academic center instead of in a community setting?
What kind of infrastructure is needed to administer these agents in the community setting that poses key challenges?
How are you partnering with academic or community centers to support these patients? What is your internal referral pathway?